Matthew J. Walter, M.D www.sildenafilcitrate.net ., Dong Shen, M.D., Ph.D., Li Ding, Ph.D., Jin Shao, M.S., Daniel C. Koboldt, M.S., Ken Chen, Ph.D., David E. Larson, Ph.D., Michael D. McLellan, B.S., David Dooling, Ph.D., Rachel Abbott, B.S., Robert Fulton, M.S., Vincent Magrini, Ph.D., Heather Schmidt, B.S., Joelle Kalicki-Veizer, B.S., Michelle O’Laughlin, B.S., Xian Lover, M.S., Marcus Grillot, B.S., Sarah Witowski, M.A., Sharon Heath, John L. Frater, M.D., William Eades, Michael Tomasson, M.D., Peter Westervelt, M.D., Ph.D., John F.
All reported components of the primary outcome and recurrent angina had been reviewed by an adjudication committee whose members were unacquainted with study-group assignments. Statistical Analysis We calculated that a sample size of 4700 patients would give a power of 80 percent to detect a 28 percent relative risk decrease in the rate of the first coprimary outcome at 30 days and a power of 90 percent to detect a 20 percent relative risk reduction in the rate of the next coprimary outcome at 5 years. An unbiased safety and data monitoring panel reviewed the interim analyses of efficacy data. Three formal interim analyses for basic safety and efficacy were prepared and undertaken when 25 percent, 50 percent, and 75 percent of the 30-day time follow-up data were obtainable.